IL3 and chronic myelogenous leukemia, BCR-ABL1 positive: IL3-exosomes armed with imatinib target CML blasts and transported imatinib and BCR-ABL1-silencing RNA, with a consequent reduction in leukemia cell proliferation in vitro and in vivo and imatinib-resistant cells [172].